2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3670 A novel chemotherapy-free triplet of pirtobrutinib, lisaftoclax, and rituximab for relapsed/refractory DLBCL: A prospective single-arm phase II study

Ping Nana, Aining Liu2, Qian Zhu3, Junhong Li4, Xiao Zhang5, Danqing Kong6, Fan Xia7, Rui Zou8, Siyun He9, Depei Wu Sr, MD10, Zhengming Jin11, Changju Qu, PhD12
2 Department of Hematology, Affiliated Hospital of Jiangnan University, China 214062, wuxi, China
3 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
5 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
6 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
7 Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou, China
8 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
9 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
10 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
11 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

Background:

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy. Although first-line chemoimmunotherapy yields relatively high response rates, approximately 40% of patients eventually progress to the relapsed or refractory (R/R) setting, where conventional salvage therapies provide limited benefit (overall response rate [ORR]: 30%–60%). To move beyond the cytotoxicity of chemotherapy, we designed a chemotherapy-free regimen. This novel strategy (PVR) integrated pirtobrutinib, a highly selective non-covalent BTK inhibitor, with lisaftoclax, an emerging BCL-2 inhibitor distinguished by its improved safety profile, alongside rituximab. This study was undertaken to assess whether this targeted, non-cytotoxic combination PVR regimen can significantly boost response rates with favorable safety for R/R DLBCL patients.

Methods:

This prospective, single-arm phase II study (NCT07255963) enrolled patients with R/R DLBCL who had received ≥1 prior lines of therapy. Eligible patients were treated with two 28-day PLR induction cycles comprising pirtobrutinib 200 mg once daily, lisaftoclax (200 mg once daily on d1-d7, 400mg once daily on d8-d28 for cycle 1, 400mg once daily for cycle 2) and rituximab 375 mg/m² on day 1. The primary endpoint was objective response rate (ORR) after induction. Secondary endpoints included complete remission rate (CRR) after induction and safety during induction.

Results:

At data cut-off (July 23, 2026), 10 patients were enrolled, with a median age of 69 years (range, 22-74), and 5 patients (50%) were male. Patients had received a median of 3 prior lines of therapy (range, 1–6) . Based on cell-of-origin classification (Han’s algorithm), 4 patients (40%) were germinal center B-cell-like (GCB) subtype, and 6 patients (60%) were non-GCB subtype. The baseline characteristics of the enrolled patients were as follows: the majority of (90%) patients had advanced-stage disease. Seven patients (70%) had elevated lactate dehydrogenase (LDH) levels, and five (50%) presented with extranodal involvement. All patients were with an International Prognostic Index (IPI) ≥2, including seven (70%) with IPI of 4-5. The ORR after induction treatment was 90%, with a CR rate (CRR) of 20%. With a median follow-up of 10.1 months (range, 1.8-10.2), the median progression-free survival (PFS) was 10.2 months (range, 1.8–not reached [NR]), and the 10-month PFS rate was 54.9% (95% CI, 18.7–80.6). The median overall survival (OS) was not reached, with a 10-month OS rate of 100% (95% CI, NR–NR). Adverse events (AEs) of any grade were observed in 10 (100%) patients, with 8 patients (80%) reporting grade ≥3 AEs during induction therapy. The most common AEs were thrombocytopenia (any grade, 100%; grade ≥3, 30%), anemia (any grade, 90%; grade ≥3, 40%) and neutropenia (any grade, 70%; grade ≥3, 60%). Non-hematologic toxicities were observed in only 3 patients including alanine aminotransferase/aspartate aminotransferase elevation (n=2,20%) and pneumonia(n=1,10%). Notably, no severe non-hematologic toxicities were observed. All toxicities were transient and reversible. No treatment-related discontinuations or deaths were reported.

Conclusion:

This prospective study demonstrated that combining pirtobrutinib with lisaftoclax and rituximab provided significant clinical benefits for patients with R/R DLBCL, including rapid and high ORR after only 2 cycles of induction therapy and promising survival with a manageable safety profile. These preliminary findings supported this combination as a valuable chemo-free approach for R/R DLBCL. Further validation with extended patient enrollment is warranted.

Changju Qu, PhD: No relevant conflicts of interest to declare.